Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This meta-analysis evaluates the diagnostic value of SOX1 methylation across different cervical cancer types, including squamous cell carcinoma and adenocarcinoma, to assess its efficacy as a biomarker.
Methods: We reviewed studies published up to March 2024, employing a PICOS-based search strategy in databases like PubMed and Web of Science. We included clinical studies providing diagnostic performance indicators while excluding non-clinical and small-sample studies. Meta-Disc1.4 and Stata15.1 were used for statistical analyses focusing on SOX1 methylation's sensitivity, specificity, and diagnostic odds ratio.
Results: Twelve articles encompassing 18 studies with 3,213 subjects were analyzed. The overall DOR for SOX1 methylation in cervical cancer diagnosis was 68.95 (95%CI: 27.63-172.07), with a Summary Receiver Operating Characteristic AUC of 0.92, indicating high diagnostic accuracy. Specifically, the DOR for adenocarcinoma was 87.57 (95%CI: 7.05-1087.44) with an AUC of 0.89, and for squamous cell carcinoma, it was 245.87 (95% CI: 26.49-2282.40) with an AUC of 0.93, reflecting significant diagnostic potential for both cancer types. No substantial publication bias was detected (P > 0.10).
Conclusion: SOX1 gene methylation demonstrates significant diagnostic value for both adenocarcinoma and squamous cell carcinoma of the cervix, particularly effective in large sample sizes and cervical exfoliated cell samples for early detection and screening, supporting its utility as a reliable biomarker.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013204 | PMC |
| http://dx.doi.org/10.1186/s12957-025-03790-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A urinary DNA methylation assay using two genes enables noninvasive detection and prognostic prediction in urothelial carcinoma.
Sci Rep
August 2025
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Guangzhou, 510080, China.
The incidence of urothelial carcinoma (UC) ranks second among all urological cancers, accounting for over 90% of malignant tumors in bladder. Patients diagnosed with UC experience a lower quality of life due to rapid progression of the disease. Early and non-invasive detection is curial for diagnosing UC and improving patient outcomes.
View Article and Find Full Text PDFHypermethylation of and Genes Is Associated with Clinicopathologic Characteristics of Non-Small Cell Lung Cancer Patients.
Curr Issues Mol Biol
May 2025
Pulmonology Clinic, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
DNA methylation changes, especially hypermethylation of and HOXA9, may serve as biomarkers for diagnosis and prognosis in non-small cell lung carcinoma (NSCLC). This study analyzed the methylation status of and in 63 primary NSCLC tumor samples, corresponding normal lung tissues, and circulating blood, using bisulfite pyrosequencing. The relationship between methylation patterns and clinicopathologic features was also explored.
View Article and Find Full Text PDFPAX1/SOX1 gene methylation as a detection and triage method for triage of high risk HPV-Positive women in cervical cancer screening.
Gynecol Oncol Rep
August 2025
Department of Clinical Laboratory, Bijie Maternal and Child Health Care Hospital, Guizhou 551600, PR China.
Objective: To evaluate the role of PAX1/SOX1 methylation testing in the triage of HPV-positive patients and compare its performance with traditional screening methods, including HPV genotyping and cytology.
Methods: A study was conducted from February 2024 to October 2024, involving women referred for colposcopy during the "two-cancer screening" in a specific region. Patients were grouped based on histopathological results [normal/cervicitis, cervical intraepithelial neoplasia 1 (CIN1), high-grade squamous intraepithelial lesion (HSIL), cervical cancer] and high-risk human papillomavirus (hrHPV) typing (HPV16/18 positive, other 12 hrHPV positive).
Meta-analysis of the diagnostic value of SOX1 methylation in different types of cervical cancer.
World J Surg Oncol
April 2025
Department of Gynecology, Taiyuan Centre Hospital/The Ninth Clinical Medical College of Shanxi Medical University, Fendong Street, Xiaodian District, Taiyuan, 030032, Shanxi, China.
Objective: This meta-analysis evaluates the diagnostic value of SOX1 methylation across different cervical cancer types, including squamous cell carcinoma and adenocarcinoma, to assess its efficacy as a biomarker.
Methods: We reviewed studies published up to March 2024, employing a PICOS-based search strategy in databases like PubMed and Web of Science. We included clinical studies providing diagnostic performance indicators while excluding non-clinical and small-sample studies.
Analysis of the triage value of multigene methylation testing for CIN2 + in hrHPV-positive patients.
Infect Agent Cancer
April 2025
Hainan Women and Children's Medical Center, No.75, Longkunnan Road, Haikou, Hainan, 570206, China.
Objective: To assess the triage value of multigene methylation testing for cervical intraepithelial neoplasia 2 and above (CIN2+) in high-risk human papillomavirus (hrHPV) positive patients.
Methods: 634 hrHPV-positive cases were selected from the gynecology outpatient clinic at Hainan Women and Children's Medical Center between July 2022 and April 2024. Out of these, 274 patients were excluded based on the inclusion and exclusion criteria.